nmda receptor blocker d ap5 Search Results


nmda receptor blocker dl ap5  (Alomone Labs)
94
Alomone Labs nmda receptor blocker dl ap5
Nmda Receptor Blocker Dl Ap5, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc06937972-71-24-28?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
nmda receptor blocker dl ap5 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
nmdar blockers  (Tocris)
96
Tocris nmdar blockers
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Nmdar Blockers, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc05724489-88-47-52?v=Tocris
Average 96 stars, based on 1 article reviews
nmdar blockers - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
blockers  (Tocris)
97
Tocris blockers
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Blockers, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc10720079-54-14-29?v=Tocris
Average 97 stars, based on 1 article reviews
blockers - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
glutamate receptor blockers  (Tocris)
97
Tocris glutamate receptor blockers
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Glutamate Receptor Blockers, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc10966311-644-85-97?v=Tocris
Average 97 stars, based on 1 article reviews
glutamate receptor blockers - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
2 amino 5 phosphonovaleric acid ap5  (Tocris)
97
Tocris 2 amino 5 phosphonovaleric acid ap5
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
2 Amino 5 Phosphonovaleric Acid Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc04044435-207-23-29?v=Tocris
Average 97 stars, based on 1 article reviews
2 amino 5 phosphonovaleric acid ap5 - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
nmda methyl aspartate receptor blocker d ap5  (Tocris)
97
Tocris nmda methyl aspartate receptor blocker d ap5
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Nmda Methyl Aspartate Receptor Blocker D Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pm25410428-73-8-15?v=Tocris
Average 97 stars, based on 1 article reviews
nmda methyl aspartate receptor blocker d ap5 - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
synaptic blockers  (Tocris)
95
Tocris synaptic blockers
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Synaptic Blockers, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/bio_rxiv__2023__08__26__554902-287-2-6?v=Tocris
Average 95 stars, based on 1 article reviews
synaptic blockers - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
nmdar blocker dl -2-amino-5-phosphonopentanoic acid dl -ap5  (Cayman Chemical)
90
Cayman Chemical nmdar blocker dl -2-amino-5-phosphonopentanoic acid dl -ap5
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Nmdar Blocker Dl 2 Amino 5 Phosphonopentanoic Acid Dl Ap5, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc06075724-119-16-26?v=Cayman+Chemical
Average 90 stars, based on 1 article reviews
nmdar blocker dl -2-amino-5-phosphonopentanoic acid dl -ap5 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
ap 5  (Tocris)
96
Tocris ap 5
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Ap 5, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc10103945-252-27-33?v=Tocris
Average 96 stars, based on 1 article reviews
ap 5 - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
glutamate blockers  (Tocris)
96
Tocris glutamate blockers
Suppression of potentiation of repeated <t>NMDAR</t> responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence <t>of</t> <t>D‐AP5</t> (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present
Glutamate Blockers, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+blocker+d+ap5/pmc04691326-44-33-38?v=Tocris
Average 96 stars, based on 1 article reviews
glutamate blockers - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

Image Search Results


Suppression of potentiation of repeated NMDAR responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence of D‐AP5 (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present

Journal: Glia

Article Title: G protein‐coupled receptor 37‐like 1 modulates astrocyte glutamate transporters and neuronal NMDA receptors and is neuroprotective in ischemia

doi: 10.1002/glia.23198

Figure Lengend Snippet: Suppression of potentiation of repeated NMDAR responses in CA1 pyramidal cells by GPR37L1. (a, b) Current responses to brief application of (a) kainate (3 µM, to activate kainate and AMPA receptors) and (b) NMDA (5 µM) at −30 mV were similar in Gpr37l1 +/+ and Gpr37l1 –/– slices. (c) Prolonged NMDA application evokes a slowly increasing current. (d) Repeated (at 4‐min intervals) application of NMDA (5 μM) also evoked a gradual increase in response magnitude. (e) Quantification of the increase in (d) in Gpr37l1 +/+ and Gpr37l1 –/– cells. In both Gpr37l1 +/+ and Gpr37l1 –/– slices, the response to the second application of NMDA was larger than the first. p values above bars in (e) and (g) compare with a ratio of 1. (f) As in (d) but with prosaptide (10 μM) present for the second application. (g) Prosaptide inhibited potentiation of the NMDA current in Gpr37l1 +/+ (ratio not significantly different from 1) without affecting the potentiation in the Gpr37l1 –/– [ratio ∼1.5, and not significantly different from that in (e), p = 0.15]. Numbers of cells are on bars. All recordings were in the presence of TTX (150 nM) and picrotoxin (100 µM); in (a) kainate was applied in the presence of D‐AP5 (5 μM), while in (a) and (c) NMDA was applied with NBQX (10 μM) also present

Article Snippet: Pharmacological blockers were present which increased the cell's membrane resistance and reduced currents that might be evoked by changes of [K + ] o occurring in response to a rise of extracellular glutamate concentration: TTX (150 nM, Tocris), the GABA A receptor blocker bicuculline (10 μM, Sigma), NMDAR blockers (D‐AP5, 50 μM, Tocris; (+)MK‐801, 10 μM, Sigma; 5,7‐dichlorokynurenate, 10 μM, Sigma), the AMPAR/KAR blocker (disodium NBQX, 10 μM, Sigma) and the inwardly‐rectifying potassium channel blocker (BaCl 2 , 200 μM, Sigma). d ‐aspartate (200 μM, Sigma) was added to evoke a glutamate transporter current in astrocytes (Gundersen, Shupliakov, Brodin, Ottersen, & Storm‐Mathisen, ).

Techniques: